longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

KROS

KROS
----

LongbridgeAI

Keros Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

benzinga_article
May 14, 2026 at 04:36 PM
Keros Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Source: benzinga_article The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Related Stocks

Keros Therapeutics

Keros Therapeutics

USKROS

-0.81%

VanEck Biotech ETF

VanEck Biotech ETF

USBBH

First Trust NYSE Arca Biotech Index Fd

First Trust NYSE Arca Biotech Index Fd

USFBT